Epios(TM) selected for MassChallenge Switzerland 2021 accelerator

Epios subscalp, micro-engineered, leads are validated to measure brain activity

Epios subscalp, micro-engineered, leads are validated to measure brain activity from beneath the scalp

The Wyss Center’s spin-off company Epios joins a global network of entrepreneurs with its long-term brain monitoring technology

Geneva, Switzerland, 17 May 2021 - The Wyss Center’s spin-off company, EpiosTM , has been selected to participate in the MassChallenge Switzerland 2021 accelerator program. Epios is a clinical-stage company providing personalized and precision management of neurological disorders using long-term brain monitoring and therapeutics. There were over 1000 other applicants for the accelerator which brings together leading corporates and innovation experts to support high-impact startups.

Eric Chanie , MBA, Wyss Center Entrepreneur in Residence and Co-Founder of Epios said: "We are tremendously excited to bring our Epios technology to the global community of change-makers in MassChallenge Switzerland. We believe this opportunity will be a springboard to accelerate the translation of Epios technology to the market."

The company’s first product is a subcutaneously insertable, long-term, minimally invasive, 24/7 device for brain monitoring using electroencephalography (EEG).

The device is initially targeted at people with epilepsy. In epilepsy, people often do not recognize that they have had a seizure. Long-term monitoring of brain activity during everyday life will help clinicians characterize the type and number of seizures, improve diagnosis, improve pre-surgical planning, and help build personalized treatment plans.

The Epios sensing electrodes are inserted under the skin with a simple surgical procedure. An external wearable device powers the implant and temporarily stores the data before it is uploaded to the Epios Cloud software for storage and analysis.

This new subscalp approach to EEG offers long-term, continuous, reliable recording while providing personalization and flexibility in brain coverage. Data can be collected from large areas of the brain or small focus areas depending on clinical needs.

"It is an honor for the Epios team to have been selected for MassChallenge Switzerland. Our scientists and engineers have grown Epios from an early-stage prototype to a clinical stage medical device," said Wyss Center’s CEO Mary Tolikas , PhD, MBA. "The MassChallenge accelerator now provides a remarkable opportunity for the Epios team to intensify their commercialization activities and, hopefully, reach patients around the world even faster."

MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in Boston, Israel, Mexico, Rhode Island, Switzerland, and Texas, MassChallenge is committed to strengthening the global innovation ecosystem by supporting high-potential startups across all industries, from anywhere in the world. To date, more than 2,400 MassChallenge alumni have raised more than $6.2 billion in funding, generated more than $3 billion in revenue, and created more than 157,000 total jobs.


This site uses cookies and analysis tools to improve the usability of the site. More information. |